Wellcome Trust Case Control Consortium

Home
WTCCC1 WTCCC2 WTCCC3
Information
Overview Management Committee WTCCC2 studies
WTCCC2 studies
Ankylosing Spondylitis Barrett's Oesophagus, Oesophageal Adenocarcinoma Bacteraemia Susceptibility Glaucoma Ischaemic Stroke Multiple Sclerosis Pre-eclampsia Parkinsons Disease Psychosis endophenotypes Statin Response Psoriasis Reading and Mathematics Schizophrenia Ulcerative Colitis Visceral Leishmaniasis
Press & publications
Press Release: 28/09/2005 Press Release: 06/06/2007 Publications and presentations
Data access
Access to data Approved Applications CDAC members Data formats FAQ
Open access
Available software
Participant access
Participant Login
Contact
Feedback and queries

Wellcome Trust Case Control Consortium 2

In recognition of the success of the WTCCC and to capitalise on the success of the GWA approach, a further round of GWA studies were funded in April 2008. These include 15 WTCCC-collaborative studies and 12 independent studies be supported totalling approximately 120,000 samples. Many of the studies represent major international collaborative networks that have together assembled large sample collections.

WTCCC2 will perform genome-wide association studies in 13 disease conditions: Ankylosing spondylitis, Barrett's oesophagus and oesophageal adenocarcinoma, glaucoma, ischaemic stroke, multiple sclerosis, pre-eclampsia, Parkinson's disease, psychosis endophenotypes, psoriasis, schizophrenia, ulcerative colitis and visceral leishmaniasis. WTCCC2 will also investigate the genetics of reading and mathematics abilities in children and the pharmacogenomics of statin response. Over 60,000 samples will be analysed using either the Affymetrix v6.0 chip or the Illumina 660K chip. The WTCCC2 will also genotype 3,000 controls each from the 1958 British Birth cohort and the UK Blood Service control group, and the 6,000 controls will be genotyped on both the Affymetrix v6.0 and Illumina 1.2M chips.

Data release

To support the studies within WTCCC and also the independent studies, the WTCCC will first genotype 6,000 common controls; 3,000 from the 1958 British Birth Cohort and 3,000 from the UK Blood Service Collection, and the data will be made available immediately through the existing controlled data access mechanism of the WTCCC. Data generated from the disease samples in WTCCC2 will be made available six months after data generation and QC, or upon publication.